Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 1 Cell Dose Escalation Study to Assess the Safety and Tolerability of Genetically Engineered MAGE-A10ᶜ⁷⁹⁶T in HLA-A2+ Subjects With MAGE-A10 Positive Urothelial, Melanoma or Head and Neck Tumors

NCT02989064 is registered in ClinicalTrials.gov with Adaptimmune as lead sponsor.

NCT NCT02989064
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02989064 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 1 Cell Dose Escalation Study to Assess the Safety and Tolerability of Genetically Engineered MAGE-A10ᶜ⁷⁹⁶T in HLA-A2+ Subjects With MAGE-A10 Positive Urothelial, Melanoma or Head and Neck Tumors
Lead sponsor
Adaptimmune
Phase
Phase 1
Overall status
Completed
Start date
October 31, 2016
Completion date
June 4, 2020
Enrollment
10 (actual)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

bladder urothelial carcinoma, head and neck cancer, melanoma, urothelial carcinoma